Swept Source OCT Imaging With the DREAM VG-OCT


The Intalight Dream OCT is the first combo anterior plus posterior device to perform both OCT and OCT-A at depth of 16mm. This is especially useful in patient who are very nearsighted as it allows us to image all in one frame. The intention of this study is to see how the images differ on the same patients when compared to the Cirrus OCT and to test for the repeatability of the images on a single day.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2023


  • Device: DREAM OCT
    • Swept Source OCT (similar to Zeiss Plex Elite)

Arms, Groups and Cohorts

    • All 50 patients will have both eyes (if able) imaged, 3 times, on the same day during their clinic visit.

Clinical Trial Outcome Measures

Primary Measures

  • Assessing difference in intraocular structures
    • Time Frame: Baseline
    • Assessing the performance of the DREAM VG OCT scan patterns in high myopes including glaucomatous eyes to see if there are differences in the lamina cribrosa structure when compared to patients previous Cirrus OCTs.
  • Assessing difference in intraocular vascular structures
    • Time Frame: Baseline
    • Assessing differences in vascular density in areas with presumed myopic-related field defects vs. low tension glaucoma perimetric disease

Secondary Measures

  • Assessing repeatability of scans
    • Time Frame: Baseline
    • Analyze the repeatability of quantitative RNFL and GCC parameters.

Participating in This Clinical Trial

Inclusion Criteria

  • Age greater than or equal to 18 – Myopes with spherical equivalent refraction < -4D – At least half of the subjects should have had at least one Cirrus OCT RNFL and macula performed as well as a Humphrey visual field performed in those with OCT abnormalities Exclusion Criteria:

  • Unable to comply with study imaging – unclear ocular media – Participant has, in the opinion of the investigator, any physical or mental condition that would affect the participation in the study or may interfere with the study procedures, evaluations and outcome assessments.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Robert T. Chang, MD
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Robert T. Chang, MD, Associate Professor of Ophthalmology – Stanford University
  • Overall Official(s)
    • Robert Chang, MD, Principal Investigator, Stanford University
  • Overall Contact(s)
    • Study Team, 6504975942, zacwenn@stanford.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.